Faruqi & Faruqi, LLP Issues SHAREHOLDER ALERT: Investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) Are Invited to Lead Class Action Lawsuit

New York — National securities‑law firm Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics (NASDAQ: MLTX) and is alerting investors who acquired MoonLake securities between March 10, 2024 and September 29, 2025 about their opportunity to serve as lead plaintiff in a federal class‑action lawsuit. According to the complaint, MoonLake and certain of its executives allegedly misrepresented or failed to disclose material information about the company’s Nanobody therapeutic candidate “SLK,” particularly its structural difference from monoclonal antibodies and its purported superior clinical efficacy. The complaint asserts that, contrary to earlier statements, SLK’s Nanobody design did not confer an advantage over traditional monoclonal antibodies like BIMZELX™, and that MoonLake lacked a reasonable basis for its positive claims. On September 28, 2025, MoonLake announced Week‑16 results from its Phase 3 VELA program indicating that SLK failed to demonstrate competitive efficacy relative to BIMZELX. The following day, MoonLake’s stock dropped $55.75 per share, nearly an 89.9% decline, closing at $6.24 on September 29, 2025. Investors wishing to discuss their rights or explore serving as lead plaintiff may contact partner James (Josh) Wilson of Faruqi & Faruqi at 877‑247‑4292 or 212‑983‑9330 (Ext. 1310). The deadline to move to be appointed lead plaintiff is December 15, 2025. The firm also invites whistleblowers, former employees, and shareholders with information about MoonLake’s conduct to come forward. #MoonLake #MLTX #shareholderalert #securitieslitigation #SlimScan #GrowthStocks #CANSLIM